Clinuvel Pharmaceuticals Limited · ASX:CUV

Clinuvel Pharmaceuticals — Shareholder Meeting (November 2006)

41 slides from Clinuvel Pharmaceuticals's shareholder meeting presentation, Nov 3, 2006

  1. Slide 1: Clinuvel photo-protection

  2. Slide 2: Skin darkening through photo-protection

    evements - skin darkening through jroviding photo-protection - see the company Cintvel

  3. Slide 3: Clinuvel

    Cintvel

  4. Slide 4: Hurdles between us and the finishing line

    ing line - although there are ¢ hurdles between us and Cintvel

  5. Slide 5: Photo-protection

    rotection

  6. Slide 6: Clinuvel Pharmaceuticals Limited

    suticals Limited eutical company focused on 6 candidate CUV1647 fora ed skin disorders. mful UV radiation. Cintvel

  7. Slide 7: Photo-protective drug

    -protective drug UV filter” peiboxidant ale beneficial side effect

  8. Slide 8: Clinuvel

    Cintvel

  9. Slide 9: Organ Transplant Patients

    Organ Transplant Patients Cintvel

  10. Slide 10: Clinuvel (CUV)

    Clinuvel (CUV) piPharm omnlfg Clinuvel

  11. Slide 11: Value asset CUV1647?

    alue asset CUV1647?" Cintvel

  12. Slide 12: Clinuvel

    Cintvel

  13. Slide 13: Clinuvel

    Cintvel

  14. Slide 14: Change in paradigm

    und ation — change in paradigm Cintvel

  15. Slide 15: omnlfg

    omnlfg Clinuvel

  16. Slide 16: omnlfg

    omnlfg Clinuvel

  17. Slide 17: Single molecule

    le molecule... _ # fe Clintivel

  18. Slide 18: Business development

    business development omnlfg Clinuvel

  19. Slide 19: Clinical trial organisation

    “Actiel bal by F AG bl Ingependent SWers Independent Supranational sgulators National Mecic “Ethics Com. Data Management & Org » Head Of ‘Department : = Indeper dent _ leviewers Cirtivel

  20. Slide 20: Clinuvel

    — — Clinuvel

  21. Slide 21: Evolution of medicine

  22. Slide 22: Evolution of medicine

  23. Slide 23: Evolution of medicine

  24. Slide 24: Evolution of medicine

  25. Slide 25: However you look at it

    Hewever yeu leek at it, the sage eds wi son be epeeaing octet ads vate soaker mre oe corsage wyerave seer Quitline. teydpureseoonwame 181848

  26. Slide 26: Evolution of medicine

  27. Slide 27: Cirque du Soleil

    CIRQUE DU SOLEIL e/a Clinuvel

  28. Slide 28: Organ transplant patients

    organ transplant patients ‘co-morbidity as by-product of stretching survival by suppressing foreign graft! donor organ’ ‘6% or. >1 in 20 organ transplant patients. die from SCC that arouse from AK’s’ (IMS) isolant recipient are 65 times more / (0 develop skin cancer than non ansplant patients’ omnlf

  29. Slide 29: Immune Suppressive Drugs

    oe Immune Suppressive Drugs = LE eae esa

  30. Slide 30: Immune Suppressive Drugs

    Immune Suppressive Drugs PON RNC ECC

  31. Slide 31: Immune Suppressive Drugs

    Immune Suppressive Drugs Lele ue apemtcsa

  32. Slide 32: Immune Suppressive Drugs

    Immune Suppressive Drugs Lele ue apemtcsa

  33. Slide 33: Immune Suppressive Drugs

    Immune Suppressive Drugs Lele ue apemtcsa

  34. Slide 34: Invitation to participate in Clinuvel

    est to participate in Clinuvel

  35. Slide 35: Clinuvel Assets

  36. Slide 36: Me

    Me

  37. Slide 37: Clinuvel Assets

  38. Slide 38: Milestones, Next 18 months

  39. Slide 39: Developing CUV1647 for a range of clinical needs

    eloping CUV 1647 for a range of clinical needs not addressed). used on the development of wards market approval. illion Aus) Cintvel

  40. Slide 40: BD/Clinical

    R/R BD/Clinical.. arch Assistant tant omnlfg Clinuvel

  41. Slide 41: Clinuvel

    omnlfg Clinuvel

Clinuvel Pharmaceuticals — Shareholder Meeting (November 2006) on 6ix